Revenue (GAAP) rose by 7%, reaching $10.3 million, and net loss per share (GAAP) narrowed to $0.07, both of which (GAAP) surpassed market expectations. Analysts had forecast a $0.10 loss per share ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ pipeline to focus more on complex generics—drugs that have complex ...